Lipella pharmaceuticals announces fda clearance of ind for lp-410 for oral graft-versus-host disease, advancing clinical pipeline

Clinical testing of lp-410 expected to commence in q2 2024 pittsburgh, pa, march 05, 2024 – lipella pharmaceuticals inc. (nasdaq: lipo) (“lipella,” “our,” “us” or the “company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that the u.s.
LIPO Ratings Summary
LIPO Quant Ranking